electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™

Rhea-AI Summary

electroCore, Inc. (Nasdaq: ECOR) has launched a new wellness product, Truvaga^TM, available in the U.S. via its ecommerce site, www.truvaga.com. This handheld, non-invasive vagus nerve stimulator is designed to promote general wellbeing through stress reduction, requiring only two-minute sessions without the need for apps or chargers. CEO Dan Goldberger emphasized that Truvaga is part of the company's strategy to enhance accessibility to vagus nerve stimulation technology. This move aligns with electroCore's focus on improving health outcomes through innovative therapies.

Positive

• Launch of Truvaga wellness product enhances product offerings.
• Non-invasive technology provides a drug-free solution for stress reduction.
• Ecommerce site enables direct access to consumers, potentially increasing sales.

Negative

• None.

ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called Truvaga^TM for customers residing in the United States. The new wellness product is offered through our new ecommerce site, www.truvaga.com, and promotes general wellbeing. 

Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes our proven technology to quickly and gently activate the vagus nerve. Stress affects every aspect of our lives including sleep, memory, learning, weight, fitness and more. Truvaga offers a drug-free, simple, and convenient way to help reduce stress with just 2-minute sessions, day and night; no apps, batteries, chargers or phones are required.

“The launch of a wellness product is a tremendous step forward in our company’s strategy of making vagus nerve stimulation technology more accessible to people who can benefit from harnessing the power of the vagus nerve,” stated Dan Goldberger, Chief Executive Officer at electroCore. “The Truvaga product will allow customers to incorporate vagus nerve stimulation as part of a holistic approach to improving their wellbeing.”

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic company dedicated to improving outcomes through its non-invasive vagus nerve stimulation therapy platform. The Company is focused on the treatment of multiple conditions in neurology and product offerings promoting general wellbeing and human performance. 

For more information, visit www.electrocore.com.

About Truvaga^TM
Truvaga is a handheld vagus nerve stimulator that utilizes our proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better.

For more information, please visit www.truvaga.com.

Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, wellness product offerings, new ecommerce site, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in the United States (including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

FAQ

What is Truvaga launched by electroCore?

Truvaga is a handheld, non-invasive vagus nerve stimulator designed to reduce stress and promote wellbeing.

Where can I purchase Truvaga?

Truvaga can be purchased on the ecommerce site www.truvaga.com.

What are the benefits of using Truvaga?

Truvaga offers a drug-free solution for stress reduction with quick, two-minute sessions.

When was Truvaga launched?

Truvaga was launched on December 20, 2022.

What is the stock symbol for electroCore?

The stock symbol for electroCore is ECOR.